Business Description
Collegium Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US19459J1043
Description
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.14 | |||||
| Equity-to-Asset | 0.14 | |||||
| Debt-to-Equity | 3.73 | |||||
| Debt-to-EBITDA | 2.52 | |||||
| Interest Coverage | 2.74 | |||||
| Piotroski F-Score | 7/9 | |||||
| Altman Z-Score | 1.05 | |||||
| Beneish M-Score | -2.45 | |||||
| WACC vs ROIC | ||||||
Growth Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.4 | |||||
| 3-Year EBITDA Growth Rate | 30 | |||||
| 3-Year EPS without NRI Growth Rate | 93.1 | |||||
| 3-Year Book Growth Rate | 4.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 9.55 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 10.95 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 34.37 | |||||
| 9-Day RSI | 35.45 | |||||
| 14-Day RSI | 37.5 | |||||
| 6-1 Month Momentum % | 3.64 | |||||
| 12-1 Month Momentum % | 51.33 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.97 | |||||
| Quick Ratio | 0.88 | |||||
| Cash Ratio | 0.26 | |||||
| Days Inventory | 52.96 | |||||
| Days Sales Outstanding | 115.53 | |||||
| Days Payable | 7.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | 2.7 | |||||
| Shareholder Yield % | 6.22 |
Profitability Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 62.36 | |||||
| Operating Margin % | 32.29 | |||||
| Net Margin % | 14.78 | |||||
| FCF Margin % | 32.34 | |||||
| ROE % | 42.29 | |||||
| ROA % | 7.23 | |||||
| ROIC % | 15.27 | |||||
| 3-Year ROIIC % | 13.74 | |||||
| ROC (Joel Greenblatt) % | 923.59 | |||||
| ROCE % | 25.9 | |||||
| Years of Profitability over Past 10-Year | 3 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 13.81 | |||||
| Forward PE Ratio | 4.88 | |||||
| PE Ratio without NRI | 5.16 | |||||
| Price-to-Owner-Earnings | 18.46 | |||||
| PS Ratio | 2.39 | |||||
| PB Ratio | 4.43 | |||||
| Price-to-Free-Cash-Flow | 7.85 | |||||
| Price-to-Operating-Cash-Flow | 7.79 | |||||
| EV-to-EBIT | 9.02 | |||||
| EV-to-EBITDA | 5.17 | |||||
| EV-to-Revenue | 2.99 | |||||
| EV-to-Forward-Revenue | 2.49 | |||||
| EV-to-FCF | 9.31 | |||||
| Price-to-Projected-FCF | 1.29 | |||||
| Earnings Yield (Greenblatt) % | 11.09 | |||||
| FCF Yield % | 18.54 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Collegium Pharmaceutical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 549.136 | ||
| EPS (TTM) (€) | 2.14 | ||
| Beta | 1.16 | ||
| Volatility % | 38.56 | ||
| 14-Day RSI | 37.5 | ||
| 14-Day ATR (€) | 0.962838 | ||
| 20-Day SMA (€) | 32.33 | ||
| 12-1 Month Momentum % | 51.33 | ||
| 52-Week Range (€) | 22.6 - 37.6 | ||
| Shares Outstanding (Mil) | 32.25 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 7 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Collegium Pharmaceutical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Collegium Pharmaceutical Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Collegium Pharmaceutical Inc Frequently Asked Questions
What is Collegium Pharmaceutical Inc(STU:354)'s stock price today?
The current price of STU:354 is €29.80. The 52 week high of STU:354 is €37.60 and 52 week low is €22.60.
When is next earnings date of Collegium Pharmaceutical Inc(STU:354)?
The next earnings date of Collegium Pharmaceutical Inc(STU:354) is 2025-02-21 Est..
Does Collegium Pharmaceutical Inc(STU:354) pay dividends? If so, how much?
Collegium Pharmaceutical Inc(STU:354) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers